REVIEW

Cell Research (2008): 622-640
© 2008 IBCB, SIBS, CAS All rights reserved 1001-0602/06 $ 30.00
www.nature.com/cr

New insights into the role of PML in tumour suppression

P Salomoni¹, BJ Ferguson², AH Wyllie² and T Rich³

Correspondence: P Salomoni, ps90@le.ac.uk

Download as printable (PDF) file Full Text (html)file Search Medline for articles by: P Salomoni

The PML gene is involved in the t(15;17) translocation of acute promyelocytic leukaemia (APL), which generates the oncogenic fusion protein PML (promyelocytic leukaemia protein)-retinoic acid receptor alpha. The PML protein localises to a subnuclear structure called the PML nuclear domain (PML-ND), of which PML is the essential structural component. In APL, PML-NDs are disrupted, thus implicating these structures in the pathogenesis of this leukaemia. Unexpectedly, recent studies indicate that PML and the PML-ND play a tumour suppressive role in several different types of human neoplasms in addition to APL. Because of PML's extreme versatility and involvement in multiple cellular pathways, understanding the mechanisms underlying its function, and therefore role in tumour suppression, has been a challenging task. In this review, we attempt to critically appraise the more recent advances in this field and propose new avenues of investigation.

Cell Research (2008) 18:622-640. doi: 10.1038/cr.2008.58; published online 27 May 2008

Keywords: PML, cancer, PML nuclear body, cell growth, apoptosis, senescence